A recently released expenditure report reveals that manufacture Pfizer spent $4.3 million lobbying Congress and federal agencies in the first quarter of 2010. While some of the funding was spent serving special interest partnerships like veterans’ health organizations, the bulk of the money was spent on aspects of the legislation that could lead to greater uses of the company’s products, including insurance coverage for smoking cessation products like Chantix. The action has sent up red flags to many health advocates, who expressed concern that increased prescription and availability of Chantix could lead to a rash of suicides. The FDA has reported roughly 491 cases of suicidal tendencies or behavior directly linked to usage of Chantix.
For more information on defective drugs, please visit our Defective Drugs Website.